Latest database descriptions

Aims are:
– to accelerate access to specialists for patients with schizophrenia as well as those at risk;
– to foster a personalised medical approach through a systematic and thorough investigation of schizophrenia in order to improve detection and to prevent psychiatric and somatic comorbidity; to provide personalised care recommendations from a pharmacological, psychosocial and lifestyle standpoint; to prospectively assess the impact of treatments recommended to the individual and to identify relapse risk factors;
– to reduce the time periods between the onset of disorders, accurate diagnoses and the introduction of suitable treatment;
– to improve consistency between evidence-based medical guidelines and clinical practice;
– to communicate expertise and skills using new diagnostic tools and treatment strategies.

General aim: To measure the impact of suicidal thoughts, behaviour and death in alcohol dependency.
Secondary aim: To assess clinical (psychiatric comorbidity), neuropsychological (computer IGT test) and genetic (blood sample) risk factors.

HYPOCRAS aims to compare hypoglycaemic risk in dipeptidyl peptidase-4 inhibitors (iDPP4s) with other oral antidiabetic drugs (OAD) along with metaformin in the real-life treatment of elderly patients with type 2 diabetes (T2D).

This study aims to identify the risk factors of mortality within a cohort of patients during the year following discharge from the intensive care unit.